Núñez de la VJM, Ramos ZR

Language: Spanish
References: 12
Page: 69-75
PDF size: 218.16 Kb.

ABSTRACT

Introduction: Hypophysial adenomas constitute 10-15% of all the intracranial tumors. Post-mortem examinations have found them in 20% of the population. They represent 25% of all the intracranial tumors operated. After taking care of a patient with an evident and recent hypophysial adenoma growth we intended to determine the time an adenoma takes to develop and briefly take count of the most important concepts of the hypophysial adenoma pathogenesis. Development: A short description of one clinical case is done for this revision. The following description shows how in spite of the fact that hypophysial adenoma monoclonality has been proven, even 30% of the adenomas could be polyclonal and 60% of the relapsing cases are clonally different from the original tumors. The oncogenes more frequently involved in the development of hypophysial adenomas are: gsp, gip2, type D cyclines and PTTG, whereas the most often inactivated tumor suppressor genes are: MEN-1, CNC, IFS, VHL (causative of familiar syndromes), Rb and CDK-1 (in isolated tumors). Besides the role played by the hypothalamic and hypophysial hormones,as well as the white organs in the hypophysial oncogenesis is looked over. Conclusion: The hypophysial adenomas are the most common intracranial tumors but its pathogenesis is only partially known. It is difficult to know the time taken for a hypophysial adenoma to grow. We present a case with evidence of recent grow and we revise the current knowledge in the pathogenesis of these tumors.

REFERENCES

1. Alexander JM. Tumor suppressor loss in pituitary tumors. Brain Pathol 2001; 11: 342-55.

2. Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Nature Neurosci 2002; 2: 836-49.

3. Ezzat S. The role of hormones, growth factors and their receptors in pituitary tumorigensis. Brain Pathol 2001; 11: 356-70.

4. Clayton RN, Farrel WE. Clonality of pituitary tumors: more complicated than initially envisaged? Brain Pathol 2001; 11: 313-27.

5. William’s textbook of endocrinology. 10th Ed. Editorial Elsevier; 2003. Consultado en MD consult: http://home.mdconsult.com/das/book/42351865-2/view/1091 el 11/8/04.

6. Levy A. Is monoclonality in pituitary adenomas synonymous with neoplasia? Clin Endocrinol 2000; 52: 393-7.

7. Shimon I, Melmed S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997; 82: 1675-81.

8. Yu R, Melmed S. Oncogénactivation in pituitary tumors. Brain Pathol 2001; 11: 328-41.

9. Saez C, Japón MA, Ramos-Morales F, Romero F, Segura D, Tortolero M, et al. hpttg is overexpressed in pituitary adenomas and other primary epithelial neoplasias. Oncogén1999; 18: 5473-6.

10. Kirschner LS, Sandrini F, Monbo J, Lin PJ, Carney JA, Stratakis CA. Genetic heterogenicity and spectrum of mutations of the PRKAR1A gene in patients with Carney complex. Hum Mol Gen 2000; 9: 3037-46.

11. Reubi JC, Waser B, Vale W, Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 2003; 88: 3312-20.

12. Assa SL. Transgenic and knouckout mice models clarify pituitary development, function and disease. Brain Pathol 2001; 11: 370-83.